# What the Evidence-Based Drug Policy Act of 2025 Actually Does

This bill removes a specific restriction that has been in place since 1998 preventing the federal government's drug policy office from funding or promoting certain types of drug policy research and programs. Specifically, it repeals a rule that prohibited the Office of National Drug Control Policy from spending money on efforts that might be seen as encouraging drug use—a restriction that has effectively blocked research into harm reduction strategies and alternative approaches to drug policy.

The practical impact is that this opens the door for federal funding of programs like needle exchange initiatives, supervised consumption sites, and research into drug policy approaches based on scientific evidence rather than traditional enforcement-only methods. These are programs that many public health experts argue reduce overdose deaths and disease transmission, but they've been off-limits for federal funding because of the 1998 restriction. By removing this barrier, the bill allows policymakers and researchers to pursue drug policy strategies based on what actually works according to scientific research, rather than being locked into approaches that may not be as effective.

This change primarily affects public health officials, researchers, and communities struggling with drug addiction and overdose deaths. It could lead to more federal support for treatment programs, harm reduction initiatives, and evidence-based approaches that some communities have found successful in reducing drug-related deaths and disease. However, it remains to be seen whether Congress will actually appropriate money for these purposes, and the change doesn't mandate any specific new programs—it simply removes the legal prohibition that prevented them from being funded in the first place.